The significance is the people running the trial got the enrichment right a while ago, after, I think, the first DMC report and the estimate then, after enrichment was the MACE needed to reach the primary endpoint would be around late 2019.
The enrichment was to add more placebo stage 3 CHF patients, because based on estimates then, at the first DMC announcement, the trial would not complete in a reasonable time.
I'm pretty happy with mid December 2019.
Ann: CHF P3 Trial Accrues Sufficient Primary Endpoint Events, page-15
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |